ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study

Angelo L. Gaffo1, Nicola Dalbeth2, Kenneth G. Saag3, Jasvinder Singh3, Elizabeth J. Rahn1, Amy S. Mudano3, Tuhina Neogi4, Lorenzo Cavagna5, Yi-Hsing Chen6, Ching-Tsai Lin7, Worawit Louthrenoo8, Geraldo Castelar-Pinheiro9, Fernando Perez-Ruiz10, Janitzia Vazquez-Mellado11, Maxim Eliseev12, Lisa K. Stamp13 and William Taylor14, 1Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Auckland, Auckland, New Zealand, 3University of Alabama at Birmingham, Birmingham, AL, 4Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 6Taichung Veterans General Hospital, Taichung, Taiwan, 7Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 8Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 9Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, 10Servicio de Reumatología, Vizcaya, Spain, 11Rheumatology, Hospital General de México, Mexico City, Mexico, 12Research Institute of Rheumatology of Russia, Moscow, Russian Federation, 13University of Otago, Christchurch, New Zealand, 14University of Otago, Wellington, New Zealand

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: gout, outcomes, pain and quality of life

Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Patient Perception of Gout Flares as a Measure of Outcome:

Results from an International Study

Background/Purpose: Attacks (flares) are one of the primary manifestations of gout. It is not known how infrequently gout flares need to occur for patients to consider their disease to be in remission, in a state of low activity (LDA), or in an acceptable state (PASS). In addition, it is not clear what time horizon should be used to determine these disease activity states. The aim of this study is to estimate the patient-perceived frequency of gout flares associated with disease activity states along with a clear time-horizon for these estimates

Methods: We enrolled 374 individuals with gout from 15 international sites in a cross-sectional study. We inquired about flare frequencies in the past 6 and 12 months and actual and hypothetical perception of disease states: remission (“gout is gone”), LDA (“gout control is satisfactory”) or acceptable state (“gout requires no more treatment”) with relation to flares. Data from one half of the group (discovery group) was used to estimate the best discriminatory cutpoints to distinguish remission vs. non-remission, LDA vs. no-LDA, and PASS vs. no-PASS using logistic regression. We then applied these estimates to the second half of the group (validation group) to calculate sensitivity and specificity of these thresholds. Results at 6 and 12-month recollection intervals were compared. Results: The mean age of participants was 52.7 years (SD 13.9), 90.2% were men, and 33.2% had tophi. Participants reported experiencing a median of 2 (IQR 0-4) and 3 (IQR 1-8) flares in the 6- and 12-month preceding period, respectively. From the flare perspective, 24.5% of and 22.6% of participants reported that their gout was in remission.  Flare frequency thresholds for disease states were lower with asking the participants about hypothetical (imagined) scenarios than when with their past recollection of disease states within the validation cohort (Table). Recollection of one flare or less in the prior 6 and 12 month periods provided the best predictive cutpoints between a between being or no being in remission, LAD, or PASS (Table).  Responses at 6 and 12 months had comparable performance.

Conclusion:   Recollection of one flare or less in the previous 6-month period provides the best discrimination for patient-reported gout flare remission state, although the diagnostic performance of this threshold is limited.  A 12-month recall period does not outperform a 6-month recall period for assessing gout flare disease states.

 


Disclosure: A. L. Gaffo, Cymabay, 5,AstraZeneca, 5,REVIVE, 5,AstraZeneca, 2; N. Dalbeth, AstraZeneca, 2,Takeda, 5,Crealta, 5,Cymabay, 5,AstraZeneca, 5,AstraZeneca, 9; K. G. Saag, Ardea/AstraZeneca, 5,Crealta, 5,Takeda, 5,Ardea/AstraZeneca, 2,Crealta, 2,Takeda, 2; J. Singh, Takeda Pharmaceuticals, Savient, 2,Savient, Takeda, Horizon, Regeneron, Merz, Iroko, Bioiberica, Crealta, Allergan, WebMD, UBM LLC, ACR, 5; E. J. Rahn, None; A. S. Mudano, None; T. Neogi, None; L. Cavagna, None; Y. H. Chen, None; C. T. Lin, None; W. Louthrenoo, None; G. Castelar-Pinheiro, None; F. Perez-Ruiz, None; J. Vazquez-Mellado, None; M. Eliseev, None; L. K. Stamp, None; W. Taylor, None.

To cite this abstract in AMA style:

Gaffo AL, Dalbeth N, Saag KG, Singh J, Rahn EJ, Mudano AS, Neogi T, Cavagna L, Chen YH, Lin CT, Louthrenoo W, Castelar-Pinheiro G, Perez-Ruiz F, Vazquez-Mellado J, Eliseev M, Stamp LK, Taylor W. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patient-perception-of-gout-flares-as-a-measure-of-outcome-results-from-an-international-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perception-of-gout-flares-as-a-measure-of-outcome-results-from-an-international-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology